In a decisive reversal, the Federal Circuit handed Boston Scientific Corporation a complete victory in Board of Regents of the University of Texas System v. Boston Scientific Corp., vacating a jury verdict that had found Boston Scientific’s drug-eluting coronary stent infringed the University of Texas’s patent for drug-releasing biodegradable fiber implants. The Federal Circuit
